Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 65

Fecal microbiota transplantation for treating axial spondyloarthritis

Official title: Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial

Run by University Hospital of North Norway · NCT06451588 · Data updated 2026-11-12

This study is testing if a treatment using gut bacteria from healthy donors can help people with axial spondyloarthritis who aren't feeling better with their current medications.

More Arthritis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment99 (estimated)
SponsorUniversity Hospital of North Norway
Academic / other
Locations1 site (Tromsø)
StatusRecruiting
StartedJune 1, 2024
Main results expectedMay 2027
Study endsNovember 2027
Registry record updatedAugust 14, 2026
Trial IDNCT06451588 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals diagnosed with axial spondyloarthritis who have active disease and have not found relief from NSAIDs or biologic treatments.

Probably not a fit

Patients with severe immune deficiencies, active inflammatory bowel disease, or those who have previously undergone FMT may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of fecal microbiota transplantation (FMT) in patients with axial spondyloarthritis who have not achieved satisfactory relief from biologic therapies. The study is randomized and double-blind, meaning neither the participants nor the researchers know who receives the FMT or a placebo. Participants will receive a single enema treatment and will be monitored for changes in disease activity, pain, and fatigue over a 90-day period. The trial aims to determine if FMT can restore gut microbiota composition and improve symptoms in these patients.

Why it matters

Potential benefit: If successful, this treatment could provide significant relief from symptoms for patients with axial spondyloarthritis who do not respond well to current therapies.

How similar studies have gone: While the use of fecal microbiota transplantation is a novel approach in this context, similar studies in other conditions have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Axial Spondyloarthritis according to the ASAS classification criteria
* Active disease defined as ASDAS ≥2.1 with elevated CRP ≥3 OR active inflammation on MRI within the last 3 months
* Onset of axial SpA within last 10 years
* Unsatisfactory relief of NSAIDs
* On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months OR without immunomodulatory treatment last 3 months

Exclusion Criteria:

* Planned dose adjustment or change in immunomodulatory treatment the next 90 days
* Disease or disorder with life expectancy of ≤5 years
* Severe immune deficiency (acquired, congenital og du to medication)
* Previous treatment with FMT
* Regular use of opioids with the exception of codeine and tramadol
* Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease)
* Inflammatory spinal disease other than axSpA
* Severe psychiatric disorder, alcohol- or drug abuse
* Active inflammatory bowel disease
* Microscopic colitis, diverticulitis or ileus
* Active psoriasis
* Fibromyalgia
* Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery
* Malignant disease excluding basalioma and melanoma stage 1
* Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers
* Treatment with antibiotics 12 weeks prior to study entry
* Pregnancy, lactation or planned pregnancy within the next 3 months
* Contraindications for rectal catheter insertion
* Planned rehabilitation program the next 90 days
* Limited ability to comply with protocol requirements, including biobank participation

Where it's running

  • University Hospital North Norway
    Tromsø, Norway
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.